Cancer cell invasion is one of the crucial events in local spreading, growth and metastasis of tumors. The present study investigates the mechanism underlying the antiinvasive action of the chemotherapeutic cisplatin. In human cervical carcinoma cells (HeLa), cisplatin caused a time-and concentration-dependent suppression of cell invasion through Matrigel. Inhibition of invasion was accompanied by upregulation of tissue inhibitor of matrix metalloproteinases-1 (TIMP-1), whereas levels of matrix metalloproteinase-2 (MMP-2), MMP-9 and TIMP-2 remained unchanged. Cisplatin's effects on TIMP-1 expression and invasion were associated with phosphorylations of p38 and p42/44 mitogen-activated protein kinases and were abrogated by specific inhibitors of both pathways. The impact of TIMP-1 in the anti-invasive action of cisplatin was proven by transfecting cells with small interfering RNA targeting TIMP-1, which completely reversed suppression of invasion by cisplatin. A functional relevance of TIMP-1 upregulation was substantiated by findings showing a concentration-dependent inhibition of Matrigel invasion by recombinant TIMP-1. The essential role of TIMP-1 in the anti-invasive action of cisplatin was confirmed using another human cervical carcinoma cell line (C33A) and human lung carcinoma cells (A549). Altogether, our data demonstrate a hitherto unknown mechanism by which cisplatin exerts its antimetastatic properties on highly invasive cancer cells.
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Matrix metalloproteinases (MMPs) have emerged as a group of enzymes exerting an important function during tumor invasion, metastasis and angiogenesis through degradation of extracellular matrix components such as collagens and proteoglycans (Curran and Murray, 2000; Stamenkovic, 2000) . Furthermore, tissue inhibitors of MMPs (TIMPs) have been shown to play a key role in determining the proteolytic activity of tumor tissues by regulating the activity of MMPs. Accordingly, several studies demonstrated a correlation between high invasiveness and decreased TIMP-1- (Khokha et al., 1989; Chan et al., 2005) or increased MMP-2 expression (Mori et al., 2004; Choi et al., 2005) . Conversely, the antiinvasive action of several anticarcinogenic substances has been associated with elevated TIMP-1 (Khokha et al., 1992; Park et al., 2005) or diminished MMP-2 levels (Park et al., 2005; Hong et al., 2006) .
The present study therefore focussed on cisplatin's effects on TIMP-1 and MMP-2 expression and its impact on cancer cell invasion. In view of recent studies demonstrating p38 and p42/44 MAPK activation by cisplatin (Zhang et al., 2005; Villedieu et al., 2006) and findings implying TIMP-1 as a target of MAPK signaling (Tong et al., 2004; Han and Smith, 2005) , we further investigated a possible role of both MAPKs in this respect.
To address these issues, the highly invasive cervical cancer cell line HeLa was used for Matrigel invasion assays. HeLa cells showed a decrease of invasion after a 24-h treatment with 30 mM cisplatin that became even more pronounced over the studied incubation period (Figure 1a) . Inhibition of HeLa cell invasion by cisplatin occurred in a concentration-dependent manner (Figure 1b) .
To rule out the possibility that decreased invasion by cisplatin was an unspecific cytotoxicity-related phenomenon, the time-dependent decrease of cellular viability after cisplatin exposure was analysed. According to our results, cisplatin elicited a moderate toxicity that was far below corresponding inhibitions of invasion (Figure 1b , 5 cells were seeded into 48-well plates in a volume of 500 ml serum-free Dulbecco's modified Eagle's medium (DMEM) per insert and treated with test substances or vehicles for the indicated times. Cell viability was measured using the WST-1 test (Roche Diagnostics, Mannheim, Germany). For determination of invasiveness, upper sides of transwell inserts (8-mm pore size; BD Biosciences, Oxford, UK) were coated with 28.4 mg Matrigel per insert in 24-well plates. Trypsinized and pelleted cells were suspended to a final concentration of 5 Â 10 5 cells in a volume of 500 ml serum-free DMEM per insert and treated with test substances or vehicles for the indicated times. DMEM containing 10% fetal calf serum (FCS) was used as a chemoattractant in the companion plate. Following incubation for the indicated times, the non-invaded cells on the upper surface of the inserts were removed with a cotton swab, and viability of invaded cells on the lower surface was determined. Quantification of migration was performed using the same experimental procedure without Matrigel coating. Invasion index was calculated as the absorbance at 490 nm of cells having invaded through Matrigel-coated Boyden chambers divided by absorbance of cells having migrated through uncoated control inserts with equal treatment ((invasion/ migration) Â 100%). Percent control represents comparison with vehicle-treated cells (100%) in the absence of test substance. Values are means7s.e.m. of n ¼ 4 experiments. *Po0.05, **Po0.01, ***Po0.001, vs corresponding vehicle control (a, c and d: Student's t-test; (b and e): one-way ANOVA plus Bonferroni test).
Inhibition of cancer cell invasion by cisplatin R Ramer et al compare Figure 1a and d). Accordingly, there was no significant change in invasion inhibition when Matrigel cell invasion was normalized to the corresponding cell viability instead of cell migration (i.e., invasion index): 12 h: 10777%, n ¼ 4; 24 h: 2272%, n ¼ 4, Po0.001; 48 h: 1373%, n ¼ 4, Po0.001; 72 h: 673%, n ¼ 4, Po0.001 (all values vs respective vehicle (100%), Student's t-test). Moreover, cisplatin also elicited a considerable anti-invasive action at a non-toxic concentration of 3 mM (Figure 1b) . We further tested additional antineoplastic or cytotoxic substances at equitoxic concentrations as cisplatin ( Figure 1e ). As a matter of fact, none of these compounds (i.e., 5-fluorouracil, paclitaxel, cycloheximide and C 2 -ceramide) mimicked the antiinvasive action of cisplatin.
Finally, a specific invasion-associated process was substantiated by the finding that reduced invasion was not associated with decreased cell motility (Figure 1c) . (Hinz et al., 2005) . For determination of protein levels, cell culture supernatants were centrifuged and concentrated using Microcon YM-10 centrifugal filter units (Millipore GmbH, Schwalbach, Germany) with a 10 kDa cutoff. Western blot analysis was performed as described (Hinz et al., 2005) using specific antibodies raised to TIMP-1, MMP-2, TIMP-2 and MMP-9 (Oncogene Research Products, San Diego, CA, USA). To control for loading of equal protein amounts, transferred proteins on Western blot membranes were stained with the fluorescent dye Roti-Green (Carl Roth, Karlsruhe, Germany). As corresponding standard a band with a size of about 65 kDa which appeared unregulated was chosen as loading control (LC). Densitometric analysis of TIMP-1 band intensities (normalized to loading control) was achieved by an optical scanner and the Multi-Analyst program, version 1.1 (Bio-Rad Laboratories, Hercules, CA, USA). In RT-PCR experiments (a) and densitometric analyses (b and c), percent control represents comparison with vehicle-treated cells (100%) in the absence of test substance. Values are means7s.e.m. of n ¼ 4-8 (RT-PCR) or n ¼ 5 (densitometry) experiments. *Po0.05 vs corresponding vehicle control (Student's t-test).
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Analysis of mRNA in cell lysates revealed a timedependent induction of TIMP-1 following incubation with cisplatin ( Figure 2a) . The stimulatory action of cisplatin on TIMP-1 mRNA expression became first evident after a 24-h incubation period (Figure 2a ). In line with these data, cisplatin also exhibited a time-and concentration-dependent induction of TIMP-1 protein, which was determined in cell culture supernatants (Figure 2b and c) .
Although an inhibitory action of cisplatin on MMP-2 has been described previously in small-cell lung cancer (Morikawa et al., 1995) and glioblastoma cells (Chintala et al., 1997) , cisplatin did not exhibit a significant suppression of MMP-2 mRNA (Figure 2a ) and MMP-2 protein levels (Figure 2b and c) in HeLa cells indicating a tumor-type specific modulation of this enzyme. Apart from MMP-2, cisplatin did also not influence MMP-9 and TIMP-2 expression (Figure 2c ). The observed timedependent increase of TIMP-1 and MMP-2 in vehicle controls of the respective time points (Figure 2b ) is likely due to an accumulation of TIMP-1 and MMP-2 in cell culture supernatants.
Experiments addressing the role of p38 and p42/44 MAPKs in cisplatin-elicited suppression of invasion revealed an activation of both kinases by cisplatin that became first evident after 15 min, and was still detectable after 24 and 48 h (Figure 3a ). To confirm a causal link between MAPK activations, TIMP-1 upregulation and reduction of invasiveness, cells were pretreated with inhibitors of both MAPK pathways. In fact, inhibitors of p38 MAPK activity (SB203580) and of p42/44 MAPK activation (PD98059) led to a complete reversal of cisplatin's anti-invasive and TIMP-1-inducing action (Figure 3b ). SB203580 and PD98059 given alone did not significantly influence invasiveness of and TIMP-1 expression in HeLa cells (Figure 3b ). Further inhibitor experiments imply an involvement of protein kinase C in the observed anti-invasive and TIMP-1-upregulating action of cisplatin, but exclude a contribution of the phosphatidylinositol 3-kinase (PI3K) pathway in this respect (Figure 3c) .
In an attempt to link cisplatin-induced TIMP-1 expression to the observed decrease of invasion, HeLa cells were transfected with TIMP-1 small-interfering RNA (siRNA). Monitoring of TIMP-1 secretion into the culture medium of the upper Boyden chamber confirmed a profound inhibition of TIMP-1 expression in cells transfected with TIMP-1 siRNA as compared to control samples ( Figure 4a ). As further shown in Figure 4a , knockdown of TIMP-1 expression led to an almost complete abrogation of the cisplatin-mediated decrease of invasion. By contrast, cultures treated with a non-silencing sequence exhibited the same invasion pattern as control cells treated with transfection agent only (Figure 4a ). These findings were also confirmed by staining invaded cells at the lower side of the trans-well inserts (Figure 4a ). The functional relevance of TIMP-1 upregulation was substantiated by demonstrating that recombinant TIMP-1 significantly inhibited Matrigel invasion (Figure 4c ). Specificity of siRNA targeting TIMP-1 was further proven by analysing the expression of TIMP-2 (Figure 4a ).
To exclude that the observed effects are restricted to HeLa cells, we performed key experiments in another human cervical carcinoma cell line (C33A) as well as in human lung carcinoma cells (A549). Application of cisplatin resulted in a significant inhibition of Matrigel after a 72-h incubation and on TIMP-1 and MMP-2 protein levels after a 48-h incubation period. Western blot analysis was performed as described recently (Hinz et al., 2005) Inhibition of cancer cell invasion by cisplatin R Ramer et al invasion accompanied by increased TIMP-1 secretion with both events being abolished in the presence of TIMP-1 siRNA (Figure 4b ). Likewise, a 72-h treatment with cisplatin elicited no change in cell motility (C33A: 9672%, n ¼ 4 vs vehicle (100%); A549: 10177%, n ¼ 4 vs vehicle (100%)) and only a minor loss of viability (C33A: 7775%, n ¼ 4, Po0.05 vs vehicle (100%), Student's t-test; A549: 7573%, n ¼ 4, Po0.01 vs vehicle (100%), Student's t-test) as compared to its pronounced anti-invasive action. Again, cisplatin left expression of MMP-2 and TIMP-2 virtually unaltered (Figure 4b) . Collectively, these results exclude a cell line-specific effect and suggest that selective upregulation of TIMP-1 by cisplatin may be a more general anti-invasive mechanism. However, given that the leading platinum agents in cancer chemotherapy may provoke different cellular stress responses (Hartmann and Lipp, 2003) , the anti-invasive action of carboplatin and oxaliplatin should also be addressed in future studies.
To the best of our knowledge, this is the first study that established a decisive role of TIMP-1 in the antiinvasive action of cisplatin. This hitherto unknown mechanism is expected to play an important role in the antineoplastic actions of this outstanding chemotherapeutic drug.
